RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

212

Participants

Timeline

Start Date

June 1, 2019

Primary Completion Date

August 31, 2025

Study Completion Date

September 30, 2026

Conditions
Cervical Cancer
Interventions
DRUG

AGEN2034

PD-1 antibody

DRUG

AGEN1884

CTLA-4 antibody

Trial Locations (68)

10016

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York

10330

King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok

10400

Ramathibodi Hospital, Mahidol University, Bangkok

10449

Mackay Memorial Hospital Taipei Branch, Taipei

10461

Albert Einstein College of Medicine, The Bronx

11042

Northwell Health Monter Cancer Center, Lake Success

11217

Taipei Veterans General Hospital, Taipei

11259

Koo Foundation Sun Yat-Sen Cancer Center, Taipei

13210

SUNY Upstate Medical University, Syracuse

15023

Clinica MonteSur, Centro de Investigación Clínica Montesur RCI -259, Lima Lima

17403

WellSpan Gynecologic Oncology, York

28204

Levine Cancer Institute, Charlotte

28374

FirstHealth Outpatient Cancer Center, Pinehurst

30342

Northside Hospital, Atlanta

32207

Baptist MD Anderson Cancer Center, Jacksonville

33612

Moffitt Cancer Center, Tampa

36604

University of South Alabama Mitchell Cancer Institute, Mobile

40536

University of Kentucky Albert B. Chandler Hospital, Lexington

40705

Taichung Veterans General Hospital, Taichung

43210

The Ohio State University Wexner Medical Center, Columbus

43215

Columbus NCORP, Columbus

44109

MetroHealth Medical Center, Cleveland

46250

Community Health Network - North Cancer Center, Indianapolis

64570

Christus Muguerza Hospital Vidriera, Monterrey

68000

Oaxaca Site Management Organization (OSMO), Oaxaca City

70121

Ochsner Clinic Foundation, New Orleans

74146

Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa

75231

Texas Oncology - Dallas - Presbyterian Cancer Center, Dallas

75390

The University of Texas Southwestern Medical Center, Dallas

75702

Texas Oncology, Tyler

76022

Texas Oncology - Bedford, Bedford

76090

Cancerologia De Queretaro, Querétaro

76104

Texas Oncology - Fort Worth Cancer Center, Fort Worth

77380

Texas Oncology - The Woodlands, The Woodlands

78240

Texas Oncology - San Antonio Medical Center, San Antonio

78745

Texas Oncology Surgical Specialists - Austin Central, Austin

85016

Arizona Oncology - Biltmore Cancer Center, Phoenix

85711

Arizona Oncology - Tucson - Wilmot Road Location, Tucson

87102

University of New Mexico Cancer Center, Albuquerque

90095

UCLA- Women's Health Clinical Research Unit (WHCRU), Los Angeles

92093

University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla

92663

Gynecologic Oncology Associates, Newport

94158

University of California, San Francisco Medical Center, San Francisco

97227

Northwest Cancer Specialists, P.C., Portland

97401

Willamette Valley Cancer Institute, Eugene

35233-1802

University of Alabama at Birmingham School of Medicine, Birmingham

94115-1821

California Pacific Medical Center, San Francisco

31405-6015

St Joseph's Hospital, Savannah

08103

MD Anderson Cancer Center at Cooper, Camden

73104-5418

Stephenson Cancer Center, Oklahoma City

19104-5127

Penn Medicine - Jordan Center for Gynecologic Cancer, Philadelphia

02905

Women & Infants Hospital of Rhode Island, Providence

60336-045

CRIO - Centro Regional Integrado de Oncologia, Fortaleza

29043-260

Hospital Santa Rita, Vitória

50070-902

IMIP - Instituto de Medicina Integral Prof. Fernando Figueira, Recife

98700-000

ONCOSITE/Hospital de Caridade de Ijuí, Ijuí

90110-270

Hospital Mãe de Deus, Porto Alegre

69304-015

CECOR - Centro Oncológico de Roraima, Boa Vista

14784-400

Hospital de Câncer de Barretos, Barretos

20231-050

INCA - Instituto Nacional de Câncer, Rio de Janeiro

01246-000

Instituto do Câncer do Estado de São Paulo, São Paulo

01317-001

Perola Centro de Pesquisa em Oncologia, São Paulo

17210-120

Hospital Amaral Carvalho, São Paulo

9015-010

Fundação Antonio Prudente/AC Camargo Cancer Center, São Paulo

04700

COI Centro Oncológico Internacional S.A.P.I. de C.V., Mexico City

03080

Seoul National University, Seoul

06273

Gangnam Severence Hospital, Seoul

Unknown

Samsung Medical Center, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

GOG Foundation

NETWORK

lead

Agenus Inc.

INDUSTRY

NCT03894215 - RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer | Biotech Hunter | Biotech Hunter